Influence of quitting smoking on diabetes-related complications: A scoping review with a systematic search strategy.

Introduction: Smoking in people with diabetes markedly elevates their risk of developing complications and increases the likelihood of cardiovascular mortality. This review is the first to specifically provide evidence-based analysis about the influence of quitting smoking on diabetes-related complications in people with type 2 diabetes.
Method: The present review was carried out according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) Extension for Scoping Reviews. All human clinical studies assessing the effects of stopping smoking cessation on diabetes-related complications were included. PubMed and Embase were screened until January 2024. References of primary studies and principal peer-reviewed scientific journals in the field were manually screened.
Results: We identified a total of 1023 studies. Only 26 met the criteria for eligibility. In general quitting smoking is associated with decreased risks of myocardial infarction and ischemic stroke. Regarding microvascular complications, the strongest evidence for the beneficial effects of smoking cessation is observed in diabetic nephropathy. However, the relationship between smoking cessation and retinopathy, neuropathy, diabetic foot complications and diabetic-related erectile dysfunction, is poorly investigated.
Conclusion: Quitting smoking offers significant advantages in managing diabetes-related complications, significantly lowering the risks of myocardial infarction, ischemic stroke, and diabetic nephropathy. This underscores the importance of cessation. Providing evidence-based information on the benefits of stopping smoking for people with type 2 diabetes who smoke, can bolster smoking cessation efforts in the context of diabetes management.
Competing Interests: Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests:Magdalena Walicka reports a relationship with Sanofi that includes: speaking and lecture fees and travel reimbursement. Magdalena Walicka reports a relationship with AstraZeneca that includes: speaking and lecture fees. Magdalena Walicka reports a relationship with Novo Nordisk that includes: travel reimbursement. Magdalena Walicka reports a relationship with Berlin-Chemie that includes: travel reimbursement. Arkadiusz Krysinski reports a relationship with Eclat SRL that includes: funding grants. Arkadiusz Krysinski reports a relationship with Berlin-Chemie that includes: travel reimbursement. Giusy Rita Maria La Rosa reports a relationship with ECLAT SRL that includes: funding grants. Ang Sun reports a relationship with ECLAT SRL that includes: travel reimbursement. Ang Sun reports a relationship with University of Catania that includes: travel reimbursement. Ang Sun reports a relationship with Sbarro Institute of Health that includes: non-financial support. Riccardo Polosa reports a relationship with Elsevier, EDRA, Pfizer, Boehringer Ingelheim, Duska Therapeutics, Forest Laboratories, CV Therapeutics, Sermo Inc., GRG Health, Clarivate Analytics, Guidepoint Expert Network, and GLG Group. That includes: consulting or advisory. Riccardo Polosa reports a relationship with European Technical Committee for Standardization that includes: board membership. Riccardo Polosa reports a relationship with Center for Tobacco Prevention and Treatment (CPCT) that includes: board membership. Riccardo Polosa reports a relationship with Foundation for a Smoke-Free World, Pfizer, GlaxoSmithKline, CV Therapeutics, Sandoz, Merk Sharp & Dohme, Boehringer Ingelheim, Novartis, Arbi Group Srl., Duska Therapeutics, and Forest Laboratories that includes: funding grants. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
(Copyright © 2024 The Authors. Published by Elsevier Ltd.. All rights reserved.)